857395 | GT-11

N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide

Powder

Size SKU Packaging Price
1mg 857395P-1mg 857395P-1mg 1 x 1mg $237.31
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
(Sales Tax may apply)
Please select an option above.
${sku} - ${concentration}
GT-11

GT-11

N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide

Hygroscopic
No
Light Sensitive
No
Molecular Formula
C28H53NO3
Percent Composition
C 74.45%, H 11.83%, N 3.10%, O 10.63%
Purity
>99%
Stability
1 Years
Storage Temperature
-20°C
CAS Number
649767-83-9
CAS Registry Number is a Registered Trademark of the American Chemical Society
Formula Weight
451.725
Exact Mass
451.403
Synonyms
GT-11 dihydroceramide desaturase inhibitor

Muñoz-Guardiola P, Casas J, Megías-Roda E, Solé S, Perez-Montoyo H, Yeste-Velasco M, Erazo T, Diéguez-Martínez N, Espinosa-Gil S, Muñoz-Pinedo C, Yoldi G, Abad JL, Segura MF, Moran T, Romeo M, Bosch-Barrera J, Oaknin A, Alfón J, Domènech C, Fabriàs G, Velasco G, Lizcano JM. The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells. Autophagy. 2020 May 25:1-18. doi: 10.1080/15548627.2020.1761651. Epub ahead of print. PMID: 32397857.

 PubMed ID: 32397857

Triola G, Fabrias G, Dragusin M, Niederhausen L, Broere R, Llebaria A, van Echten-Deckert G. Specificity of the dihydroceramide desaturase inhibitor N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide (GT11) in primary cultured cerebellar neurons. Mol Pharmacol. 2004 Dec;66(6):1671-8. doi: 10.1124/mol.104.003681. Epub 2004 Sep 15. PMID: 15371559.

 PubMed ID: 15371559

Orienti I, Francescangeli F, De Angelis ML, Fecchi K, Bongiorno-Borbone L, Signore M, Peschiaroli A, Boe A, Bruselles A, Costantino A, Eramo A, Salvati V, Sette G, Contavalli P, Zolla L, Oki T, Kitamura T, Spada M, Giuliani A, Baiocchi M, La Torre F, Melino G, Tartaglia M, De Maria R, Zeuner A. A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. Cell Death Dis. 2019 Jul 23;10(7):529. doi: 10.1038/s41419-019-1775-y.

 PubMed ID: 31332161